ModifiedHealth NetPolicy CP PHAR.438

Trientine (Cuvrior, Syprine) coverage

Defines medical necessity and prior authorization criteria for Cuvrior and Syprine (trientine products) for treatment of Wilson's disease across Commercial, HIM, and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyTrientine (Cuvrior, Syprine) coverage

Policy CodePolicy CP PHAR.438

Change TypeMaterial updates: added Cuvrior dosing, redirection to generics, continued therapy template

Effective DateDec 1, 2018

Next Review DateN/A

Key ActionObtain prior authorization with documentation of Wilson's disease diagnosis and prior trials/failures of preferred generics before requesting branded trientine.

SourceLink

POLICY UPDATE CHANGES

Added new dose form, Cuvrior, and updated Appendix D regarding differing FDA indications for Cuvrior and Syprine.

Revised approval duration for Commercial line of business to 12 months or duration of request, whichever is less.

Added redirection requirement of generic trientine hydrochloride to initial approval criteria.

For continued therapy, revised to 'No COC' standard template language; references reviewed and updated.

2FDA-approved trientine products

3,000 mg/dayCuvrior max daily dose

2,000 mg/daySyprine max daily dose (>12)

12 mo

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Initial Therapy

Covered when ALL of the following are met:

Initial Approval - Wilson's disease: 1) Diagnosis of Wilson's disease; 2) Meet Wilson's disease subgroup criteria per policy (see product-specific age/indication distinctions); 3) Failure of generic penicillamine (preferred) at maximally indicated doses unless contraindicated or clinically significant adverse effects; 4) Failure of generic trientine hydrochloride at maximally indicated doses unless contraindicated or clinically significant adverse effects; 5) Requested dose does not exceed product-specific maximums (Cuvrior 3,000 mg/day and 10 tablets/day; Syprine age ≥12: 2,000 mg/day; Syprine age <12: 1,500 mg/day); 6) Age requirements for the requested product are met (Cuvrior: ≥18 years; Syprine: per age-specific dosing).see dosing thresholds

Policy prefers trials of generic penicillamine and generic trientine prior to approval of branded trientine (redirection to preferred agents).

inv-02: Continuation Therapy

Covered for continued therapy when ALL of the following are met:

Continued Therapy - Wilson's disease: 1) Member is currently receiving the medication via the plan benefit or previously met initial approval criteria; 2) Member is responding positively to therapy; 3) If the request is for a dose increase, the new dose does not exceed product-specific maximums (Cuvrior 3,000 mg/day and 10 tablets/day; Syprine age ≥12: 2,000 mg/day; Syprine age <12: 1,500 mg/day); 4) Continuity of care rules apply where state/product mandates exist as applicable.see dosing thresholds

Approval duration: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less. Continued therapy language updated to the 'No COC' standard template.

inv-03: Not Medically Necessary / Not Authorized

Not covered for the following diagnoses/indications:

Not authorized: Biliary cirrhosis; cystinuria; rheumatoid arthritis; non–FDA approved indications not addressed in this policy unless sufficient documentation supporting safety and efficacy is provided per off‑label use policies and applicable evidence of coverage documents.

Requests for indications listed as not authorized or unsupported off‑label uses are grounds for denial; provider must submit supporting documentation when seeking coverage for off‑label indications.

The following diagnoses/indications are excluded from coverage for trientine products: biliary cirrhosis, cystinuria, and rheumatoid arthritis.

Coverage determinations and administration of benefits are governed by the member's coverage documents and applicable law. Specifically, decisions are subject to all terms, conditions, exclusions, and limitations of the applicable coverage documents (for example, evidence of coverage, certificate of coverage, policy or contract of insurance), as well as state and federal requirements and Health Plan administrative policies and procedures. This clinical policy is a guide to medical necessity and does not guarantee payment.

Requests for uses that are non–FDA approved and not addressed in this policy are considered not medically necessary unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy for the member's line of business. Refer to the relevant off‑label use policy when the requested diagnosis, age, or dosing regimen is not specifically listed in this policy.

Coding and Identifiers

No explicit CPT/HCPCS/NDC codes listed in this portion of the policymixed

No codes listed

Maximum daily doses

Cuvrior (maximum)3,000 mg/day

Syprine — age >122,000 mg/day

Syprine — age <121,500 mg/day

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Requests for Cuvrior (trientine) or Syprine for treatment of Wilson's disease must have an approved prior authorization before coverage will be considered.

Policy Number: CP PHAR.438
Effective Date: 2018-12-01

Prior Authorization

Prior Authorization and Medical Necessity Guidance

Medical necessity determinations follow the Health Plan clinical policy. Initial approval requires documentation of a diagnosis of Wilson's disease and meeting the listed initial therapy criteria. Continued therapy requests must meet the continued therapy criteria in this policy (including response to therapy and dose limits). Coverage decisions remain subject to the terms, conditions, exclusions, and limitations of the member's benefit documents.

Background

Trientine products (branded as Cuvrior and Syprine) are copper‑chelating agents indicated for the treatment of Wilson's disease. Per the FDA labeling, Cuvrior is indicated for adult patients with stable, decoppered disease who are tolerant to penicillamine, while Syprine is indicated for patients who are intolerant to penicillamine. The formulations share the same active moiety, though they are not substitutable on a milligram‑for‑milligram basis and comparative clinical data across salts are limited.

Definitions

Decoppered and penicillamine tolerant

Definition (per FDA labeling)Patients with stable Wilson's disease who are decoppered and tolerant to penicillamine

Context for CuvriorCuvrior is indicated for adult patients who are decoppered and tolerant to penicillamine

Contrast with SyprineSyprine is indicated for patients intolerant of penicillamine (not the decoppered/tolerant population)

Initial Therapy Criteria

inv-19: Initial Therapy

Operational initial therapy criteria:

Initial Therapy (operational): Provider must document: diagnosis of Wilson's disease; prior trials and failures or documented contraindications/intolerance to generic penicillamine at maximally indicated doses and to generic trientine hydrochloride at maximally indicated doses before authorizing branded trientine; requested dose within product-specific maximums; age consistent with product labeling.see dosing thresholds

Supporting documentation (office notes, labs, etc.) must be submitted with the prior authorization request.

Continuation Therapy Criteria

inv-20: Continuation Therapy

Operational continuation therapy criteria:

Continuation Therapy (operational): Provider must document that the member is currently receiving the medication via the plan benefit or previously met initial criteria; the member is responding to therapy; any requested dose increase does not exceed product maximums; comply with continuity of care requirements where applicable.see dosing thresholds

Approval durations: Medicaid/HIM 12 months; Commercial 12 months or duration of request, whichever is less.

inv-21: Continued therapy

Continued therapy operational update (No COC template applied):

Continued therapy template change: Continued therapy language has been revised to the 'No COC' standard template; references were reviewed and updated. Prior authorization and medical necessity determinations remain subject to plan documents and regulatory requirements.

Step Therapy Requirements

Step	Requirement	Notes
1	Document prior trial and failure or documented contraindication/intolerance to generic penicillamine at maximally indicated doses	Per initial approval criteria: failure of generic penicillamine is required unless contraindicated or clinically significant adverse effects occurred (see Appendix B for penicillamine dosing).
2	Document prior trial and failure or documented contraindication/intolerance to generic trientine hydrochloride at maximally indicated doses	Policy added redirection requirement to generic trientine hydrochloride prior to authorizing branded trientine (operational change noted 4Q2023).
3	Requests lacking documentation of required prior trials/failures or contraindications	Authorization for branded trientine will not be granted without documentation that the above step therapy requirements are met; supporting clinical documentation (chart notes, labs) must be submitted.

Quantity Limits

Cuvrior — maximum daily dose

Cuvrior — maximum daily dose3,000 mg/day

Cuvrior dosing noteDosing regimen described as 300 mg up to 3,000 mg PO BID; not substitutable mg-per-mg with other trientine products

SourcePrescribing information and dosage administration section

Syprine (age >12) — maximum daily dose

Syprine (age >12) — maximum daily dose2,000 mg/day

Syprine dosing regimen (age >12)750–1,250 mg/day PO in divided doses two, three, or four times daily

Clinical note